Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

P Rossignol1, L Juillard2

  • 1INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, CHRU de Nancy et F-CRIN INI-CRCT, Nancy, France.

Nephrologie & Therapeutique
|February 22, 2018
PubMed
Summary

Mineralocorticoid receptor antagonists like spironolactone can treat resistant hypertension in chronic kidney disease patients. Careful monitoring for renal function and potassium levels is crucial for safe and effective use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial.

European journal of preventive cardiology·2025
Same author

Ventricular-arterial coupling (VAC) in a population-based cohort of middle-aged individuals: The STANISLAS cohort.

Atherosclerosis·2023
Same author

Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures.

Scandinavian journal of rheumatology·2023
Same author

[Suspected allergy to COVID-19 vaccines: A retrospective study of 320 patients].

Revue francaise d'allergologie (2009)·2023
Same author

NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients.

European heart journal open·2023
Same author

Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.

Pharmacological research·2022

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Hypertension is prevalent in chronic kidney disease (CKD), especially with diabetes.
  • Resistant hypertension often complicates CKD management.
  • Cardiorenal syndrome negatively impacts congestive heart failure prognosis.

Purpose of the Study:

  • To evaluate the role of mineralocorticoid receptor antagonists in managing resistant hypertension in CKD.
  • To discuss the benefits and risks of spironolactone in this patient population.
  • To explore the potential of ultrafiltration in cardiorenal syndrome.

Main Methods:

  • Review of current literature on mineralocorticoid receptor antagonists in CKD.
  • Analysis of clinical trial data for spironolactone in heart failure with reduced ejection fraction.
Keywords:
Antagoniste du récepteurCardiac failureCardiorenal syndromeChronic kidney diseaseHTA résistanteHyperkaliemiaHyperkaliémieInsuffisance cardiaqueInsuffisance rénaleMineralocorticoid receptorResistant hypertensionSyndrome cardio-rénalUltrafiltrationantagonistminéralocorticoïde

Related Experiment Videos

  • Discussion of monitoring parameters and dose adjustments.
  • Evaluation of ultrafiltration as a treatment modality.

    • Main Results:

    • Mineralocorticoid receptor antagonists have a Class 1, Level A indication for heart failure with reduced ejection fraction.
    • Potential risks include worsening renal function and hyperkalemia.
    • These risks are manageable with appropriate biological monitoring and dose adaptation.
    • Ultrafiltration shows promise when conventional treatments fail in cardiorenal syndrome.

    Conclusions:

    • Spironolactone is a potential therapeutic option for resistant hypertension in CKD patients.
    • Close monitoring of renal function and electrolytes is essential.
    • Further evaluation of ultrafiltration's role in cardiorenal syndrome is needed.